Filing exhibits
- 8-K Current report
- 3.1 Exhibit 3.1
- 3.2 Exhibit 3.2
- 10.1 Exhibit 10.1
- 10.2 Exhibit 10.2
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.11 Exhibi 10.11
- 10.12 Exhibit 10.12
- 10.13 Exhibit 10.13
- 10.20 Exhibit 10.20
- 10.21 Exhibit 10.21
- 10.22 Exhibit 10.22
- 10.23 Exhibit 10.23
- 10.24 Exhibit 10.24
- 10.25 Exhibit 10.25
- 10.26 Exhibit 10.26
- 10.27 Exhibit 10.27
- 10.28 Exhibit 10.28
- 10.28 Exhibit 10.28(A)
- 14.1 Exhibit 14.1
- 16.1 Exhibit 16.1
- 23.1 Exhibit 23.1
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- 99.5 Exhibit 99.5
- 99.6 EXHIBIT99.6
- Download Excel data file
- View Excel data file
Table of Contents
Cover
Cover | Jul. 21, 2023 |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 21, 2023 |
Current Fiscal Year End Date | --12-31 |
Entity File Number | 001-40021 |
Entity Registrant Name | AEON Biopharma, Inc. |
Entity Central Index Key | 0001837607 |
Entity Tax Identification Number | 85-3940478 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 5 Park Plaza, |
Entity Address, Address Line Two | Suite 1750 |
Entity Address, City or Town | Irvine |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92614 |
City Area Code | 949 |
Local Phone Number | 354-6499 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
Common Stock [Member] | |
Title of 12(b) Security | Class A common stock, $0.0001 par value per share |
Trading Symbol | AEON |
Security Exchange Name | NYSE |
Warrant [Member] | |
Title of 12(b) Security | Warrants to purchase Class A common stock |
Trading Symbol | AEON WS |
Security Exchange Name | NYSE |